Current insights on human Papillomavirus-independent cervical cancers: a systematic review
DOI:
https://doi.org/10.1590/s2175-97902025e24596Keywords:
Prognosis, Presentation, Cervical cancer, HPV DNA-independentAbstract
A small subset of cervical cancers tests negative for human Papillomavirus (HPV) DNA, being associated with poorer prognosis and higher aggressiveness. This study systematically reviewed the current status of HPV DNA-independent cervical cancers from clinical, diagnostic and prognostic perspectives, in comparison to HPV-associated cervical cancers. Relevant terms were searched in databases including PubMed, EMBASE, LILACS, Web of Science, Scopus, CINAHL and the Cochrane Controlled Trials Registered between January 2018 and December 2023. We focused on studies published in peer-reviewed English-language with available abstracts. Researchers independently screened the titles and abstracts and the selected articles were then read in full text. After reaching a consensus, 31 papers were selected for data extraction. Various techniques were employed for HPV testing, primarily based on polymerase chain reaction (PCR) and different types of clinical samples were analyzed. A total of 9.2% of the cases were found to be HPV-negative (mean age of 55.8 years). HPV-independent cervical cancers exhibit distinct characteristics; however, several challenges in interpreting the data were identified. Our findings demonstrate the difficulty in distinguishing truly HPV-independent cervical cancers from false-negative ones. Moreover, there is a critical need for new, more comprehensive and rigorously controlled studies to better elucidate the complexities surrounding HPV-independent cervical cancers.
Downloads
References
Abreu AL, Souza RP, Gimenes F, Consolaro ME. A review of methods for detect human Papillomavirus infection. Virol J. 2012;9:262.
Akagi K, Li J, Broutian TR, Padilla-Nash H, Xiao W, Jiang B, et al. Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res. 2014;24(2):185-199.
Banister CE, Liu C, Pirisi L, Creek KE, Buckhaults PJ. Identification and characterization of HPV-independent cervical cancers. Oncotarget. 2017;8(8):13375-13386.
Blatt AJ, Kennedy R, Luff RD, Austin RM, Rabin DS. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015;123(5):282-288.
Bulutay P, Haberal N, Ozen O, Erdem O, Zeren EH, Kulac I, et al. Reproducibility of Morphologic Parameters of the International Endocervical Adenocarcinoma Criteria and Classification System and Correlation With Clinicopathologic Parameters: A Multi-Institutional Study. Int J Gynecol Pathol. 2022;41(5):447-458.
Castro FA, Koshiol J, Quint W, Wheeler CM, Gillison ML, Vaughan LM, et al. Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods. BMC Infect Dis. 2015;15:544.
Chen H, Gu L, Zhang M, Chen H, Liao H, Cao X, et al. Interaction of miR-200a-3p with YAP regulates cell proliferation and metastasis differentially in HPV-positive and HPV-negative cervical cancer cells. BMC Cancer. 2022a;22(1):1039-1039.
Chen L, Lucas E, Zhang X, Liu Q, Zhuang Y, Lin W, et al. Programmed death-ligand 1 expression in human papillomavirus-independent cervical adenocarcinoma and its prognostic significance. Histopathology. 2022b;80(2):338-347.
Chong GO, Han HS, Park JY, Lee SD, Lee YH, Lee HJ, et al. Prevalence, survival outcomes, and clinicopathologic factors associated with negative high risk human papillomavirus in surgical specimens of cervical cancer with pretreatment negative DNA genotype test. Int J Gynecol Cancer. 2019;29(1):10-16.
Chong GO, Lee YH, Han HS, Lee HJ, Park JY, Hong DG, et al. Prognostic value of pre-treatment human papilloma virus DNA status in cervical cancer. Gynecol Oncol. 2018;148(1):97-102.
Cuzick J, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Ho L, et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer. 2013;108(4):908-913.
de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-1056.
Diop-Ndiaye H, Sastre-Garau X, Drame A, Dembele B, Ba NN, Diop-Diongue O, et al. Respective prevalence of high-risk HPV genotypes in cervical neoplasia in Senegal. J Med Virol. 2021;93(8):5110-5117.
Du X, Hu Y, Ji X, Sui L, Zheng Q, Song K, et al. Membranous and nuclear staining of CLDN18 in HPV-independent and HPV-associated endocervical adenocarcinomas. Cancer Med. 2023;12(2):1441-1450.
Dürst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A. 1983;80(12):3812-3815.
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021;149(4):778-789.
Geraets D, Alemany L, Guimera N, de Sanjose S, de Koning M, Molijn A, et al. Detection of rare and possibly carcinogenic human papillomavirus genotypes as single infections in invasive cervical cancer. J Pathol. 2012;228(4):534-543.
González-Bosquet E, Muñoz A, Suñol M, Lailla JM. Cervical cancer and low-risk HPV; a case report. Eur J Gynaecol Oncol. 2006;27(2):193-194.
Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131(10):2349-2359.
Guimerà N, Lloveras B, Alemany L, Iljazovic E, Shin HR, Jung-Il S, et al. Laser capture microdissection shows HPV11 as both a causal and a coincidental infection in cervical cancer specimens with multiple HPV types. Histopathology. 2013a;63(2):287-292.
Guimerà N, Lloveras B, Lindeman J, Alemany L, van de Sandt M, Alejo M, et al. The occasional role of low-risk human papillomaviruses 6, 11, 42, 44, and 70 in anogenital carcinoma defined by laser capture microdissection/PCR methodology: results from a global study. Am J Surg Pathol. 2013b;37(9):1299-1310.
Hallowell BD, Saraiya M, Thompson TD, Unger ER, Lynch CF, Tucker T, et al. Population-based assessment of HPV genotype-specific cervical cancer survival: CDC Cancer Registry Sentinel Surveillance System. JNCI Cancer Spectrum. 2018;2(3):pky036.
Hirose S, Murakami N, Takahashi K, Kuno I, Takayanagi D, Asami Y, et al. Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients. Gynecol Oncol. 2020;156(1):203-210.
Hodgson A, Howitt BE, Park KJ, Lindeman N, Nucci MR, Parra-Herran C. Genomic Characterization of HPV-related and Gastric-type Endocervical Adenocarcinoma: Correlation With Subtype and Clinical Behavior. Int J Gynecol Pathol. 2020;39(6):578-586.
Holl K, Nowakowski AM, Powell N, McCluggage WG, Pirog EC, Collas De Souza S, et al. Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study. Int J Cancer. 2015;137(12):2858-2868.
Höhn AK, Brambs CE, Hiller GGR, May D, Schmoeckel E, Horn LC. 2020 WHO Classification of Female Genital Tumors. Geburtshilfe Frauenheilkunde. 2021;81(10):1145-1153.
IARC. Cervical cancer screening. IARC handbooks of cancer prevention. Vol. 18. Lyon, France: International Agency for Research on Cancer; 2022.
Ibragimova M, Tsyganov M, Shpileva O, Churuksaeva O, Bychkov V, Kolomiets L, et al. HPV status and its genomic integration affect survival of patients with cervical cancer. Neoplasma. 2018;65(3):441-448.
Jenkins D, Molijn A, Kazem S, Pirog EC, Alemany L, de Sanjosé S, et al. Molecular and pathological basis of HPV-negative cervical adenocarcinoma seen in a global study. Int J Cancer. 2020;147(9):2526-2536.
Jung H, Bae GE, Kim HM, Kim HS. Clinicopathological and Molecular Differences Between Gastric-type Mucinous Carcinoma and Usual-type Endocervical Adenocarcinoma of the Uterine Cervix. Cancer Genomics Proteomics. 2020;17(5):627-641.
Kaliff M, Karlsson MG, Sorbe B, Bohr Mordhorst L, Helenius G, Lillsunde-Larsson G. HPV-negative Tumors in a Swedish Cohort of Cervical Cancer. Int J Gynecol Pathol. 2020;39(3):279-288.
Karamurzin YS, Kiyokawa T, Parkash V, Jotwani AR, Patel P, Pike MC, et al. Gastric-type Endocervical Adenocarcinoma: An Aggressive Tumor With Unusual Metastatic Patterns and Poor Prognosis. Am J Surg Pathol. 2015;39(11):1449-1457.
Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12(7):663-672.
Kinoshita R, Mitamura T, Kato F, Hattori T, Higaki H, Takahashi S, et al. Distribution of human papilloma virus genotypes and treatment outcomes in definitive radiotherapy for cervical cancer. J Radiat Res. 2023;64(2):463-470.
Kugelman N, Siegler E, Mackuli L, Lavie O, Schmidt M, Shaked-Mishan P, et al. Prognosis of Human Papillomavirus-Negative Compared to Human Papillomavirus-Positive Cervical Cancer. J Low Genit Tract Dis. 2022;26(2):115-121.
Lee JE, Chung Y, Rhee S, Kim TH. Untold story of human cervical cancers - HPV-negative cervical cancer. BMB Rep. 2022;55(9):429-438.
Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128(4):927-935.
Liu Y, Li M, Yu H, Piao H. LncRNA SRA1 is down-regulated in HPV-negative cervical squamous cell carcinoma and regulates cancer cell behaviors. Biosci Rep. 2019;39(8):BSR20191226.
Liu Y, Liu H, Sheng B, Pan S, Wang ZW, Zhu X. The functions of lncRNAs in the HPV-negative cervical cancer compared with HPV-positive cervical cancer. Apoptosis. 2022;27(9-10):685-696.
Liu Y, Xu Y, Jiang W, Ji H, Wang ZW, Zhu X. Discovery of key genes as novel biomarkers specifically associated with HPV-negative cervical cancer. Mol Ther Methods Clin Dev. 2021;21:492-506.
Lu LH, Liu TQ, Wang SN, Li J, Zhang FR, Ning Y, et al. Joint detection of multiple HPV-testing technologies and evaluation of clinicopathological characteristics discriminate between HPV-independent and low-copy HPV-associated cervical squamous cell carcinoma (CSCC) -an analysis of 3869 cases. Gynecol Oncol. 2023;170:59-69.
Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180-e190.
McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55-61.
Mills AM, Dirks DC, Poulter MD, Mills SE, Stoler MH. HR-HPV E6/E7 mRNA In Situ Hybridization: Validation Against PCR, DNA In Situ Hybridization, and p16 Immunohistochemistry in 102 Samples of Cervical, Vulvar, Anal, and Head and Neck Neoplasia. Am J Surg Pathol. 2017;41(5):607-615.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009;3(3):e123-130.
Mühr LSA, Lagheden C, Lei JY, Eklund C, Kleppe SN, Sparen P, et al. Deep sequencing detects human papillomavirus (HPV) in cervical cancers negative for HPV by PCR. Br J Cancer. 2020;123(12):1790-1795.
Nicolás I, Marimon L, Barnadas E, Saco A, Rodríguez-Carunchio L, Fusté P, et al. HPV-negative tumors of the uterine cervix. Mod Pathol. 2019;32(8):1189-1196.
Nishio S, Mikami Y, Tokunaga H, Yaegashi N, Satoh T, Saito M, et al. Analysis of gastric-type mucinous carcinoma of the uterine cervix - An aggressive tumor with a poor prognosis: A multi-institutional study. Gynecol Oncol. 2019;153(1):13-19.
Okuma K, Yamashita H, Yokoyama T, Nakagawa K, Kawana K. Undetected human papillomavirus DNA and uterine cervical carcinoma: Association with cancer recurrence. Strahlenther Onkol. 2016;192(1):55-62.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:71.
Park KJ. Cervical adenocarcinoma: integration of HPV status, pattern of invasion, morphology and molecular markers into classification. Histopathology. 2020;76(1):112-127.
Petry KU, Liebrich C, Luyten A, Zander M, Iftner T. Surgical staging identified false HPV-negative cases in a large series of invasive cervical cancers. Papillomavirus Res. 2017;4:85-89.
Pirog EC, Lloveras B, Molijn A, Tous S, Guimerà N, Alejo M, et al. HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Mod Pathol. 2014;27(12):1559-1567.
Poljak M. Towards cervical cancer eradication: joint force of HPV vaccination and HPV-based cervical cancer screening. Clin Microbiol Infect. 2015;21(9):806-807.
Poljak M, Kocjan BJ, Oštrbenk A, Seme K. Commercially available molecular tests for human papillomaviruses (HPV): 2015 update. J Clin Virol. 2016;76(Suppl 1):S3-S13.
Poljak M, Oštrbenk Valenčak A, Gimpelj Domjanič G, Xu L, Arbyn M. Commercially available molecular tests for human papillomaviruses: a global overview. Clin Microbiol Infect. 2020;26(9):1144-1150.
Ren H, Almadani N, Pors J, Leung S, Ho J, Chow C, et al. International Endocervical Adenocarcinoma Criteria and Classification (IECC): An Independent Cohort With Clinical and Molecular Findings. Int J Gynecol Pathol. 2021;40(6):533-540.
Rodríguez-Carunchio L, Soveral I, Steenbergen RD, Torné A, Martinez S, Fusté P, et al. HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis. Bjog. 2015;122(1):119-127.
Ruiz FJ, Sundaresan A, Zhang J, Pedamallu CS, Halle MK, Srinivasasainagendra V, et al. Genomic Characterization and Therapeutic Targeting of HPV Undetected Cervical Carcinomas. Cancers. 2021;13(18):4551.
Serrano B, de Sanjosé S, Tous S, Quiros B, Muñoz N, Bosch X, et al. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer. 2015;51(13):1732-1741.
Shi H, Shao Y, Zhang H, Ye L, Xu E, Lu B. Independent validation of distinct clinicopathological features and prognosis among usual-type, mucinous-type and gastric-type endocervical adenocarcinoma categorized by new WHO classification (2020). Pathology. 2022;54(5):555-562.
Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023;11(2):e197-e206.
Sitarz K, Szostek S. Food and drug administration - approved molecular methods for detecting human papillomavirus infection. Ginekol Pol. 2019;90(2):104-108.
Stolnicu S, Allison D, Praiss AM, Tessier-Cloutier B, Boroujeni AM, Flynn J, et al. Incidence and Clinicopathologic Characteristics of Human Papillomavirus-independent Invasive Squamous Cell Carcinomas of the Cervix A Morphologic, Immunohistochemical, and Human Papilloma-Virologic Study of 670 Cases. Am J Surg Pathol. 2023;47(12):1376-1389.
Stolnicu S, Barsan I, Hoang L, Patel P, Terinte C, Pesci A, et al. Stromal invasion pattern identifies patients at lowest risk of lymph node metastasis in HPV-associated endocervical adenocarcinomas, but is irrelevant in adenocarcinomas unassociated with HPV. Gynecol Oncol. 2018;150(1):56-60.
Stolnicu S, Hoang L, Chiu D, Hanko-Bauer O, Terinte C, Pesci A, et al. Clinical Outcomes of HPV-associated and Unassociated Endocervical Adenocarcinomas Categorized by the International Endocervical Adenocarcinoma Criteria and Classification (IECC). Am J Surg Pathol. 2019;43(4):466-474.
Stolnicu S, Karpathiou G, Guerra E, Mateoiu C, Reques A, Garcia A, et al. Clear Cell Carcinoma (CCC) of the Cervix Is a Human Papillomavirus (HPV)-independent Tumor Associated with Poor Outcome A Comprehensive Analysis of 58 Cases. Am J Surg Pathol. 2022;46(6):765-773.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
Tjalma WA, Depuydt CE. Cervical cancer screening: which HPV test should be used--L1 or E6/E7? Eur J Obstet Gynecol Reprod Biol. 2013;170(1):45-46.
Tjalma WAA. HPV negative cervical cancers and primary HPV screening. Facts Views Vis Obgyn. 2018;10(2):107-113.
Tsakogiannis D, Gartzonika C, Levidiotou-Stefanou S, Markoulatos P. Molecular approaches for HPV genotyping and HPV-DNA physical status. Expert Rev Mol Med. 2017;19:e1.
Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg. 2014;12(12):1500-1524.
Vassilakos P, Tran PL, Sahli R, Low N, Petignat P. HPV-negative CIN3 and cervical cancer in Switzerland: any evidence of impact on screening policies? Swiss Med Wkly. 2017;147:w14559.
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806–808.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19.
Wang X, Wang G, Zhang L, Cong J, Hou J, Liu C. LncRNA PVT1 promotes the growth of HPV positive and negative cervical squamous cell carcinoma by inhibiting TGF-β1. Cancer Cell Int. 2018;18(1):70.
Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007;7(1):11-22.
Xing B, Guo J, Sheng Y, Wu G, Zhao Y. Human Papillomavirus-Negative Cervical Cancer: A Comprehensive Review. Front Oncol. 2020;10:606335.
Yoshida H, Shiraishi K, Kato T. Molecular pathology of human papilloma virus-negative cervical cancers. Cancers. 2021;13(24):6351.
Zhang L, Jiang Y, Lu X, Zhao H, Chen C, Wang Y, et al. Genomic characterization of cervical cancer based on human papillomavirus status. Gynecol Oncol. 2019;152(3):629-637.
Downloads
Published
Data Availability Statement
Not Informed.
Issue
Section
License
Copyright (c) 2025 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
